Altogether, our results indicate that the inhibition of CK-1δ with selective inhibitors, specifically with the benzothiazole derivative IGS-2.7 used here, might represent a good therapeutic approach for disorders involved in TDP-43 protein alterations including ALS and FTD, among others. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.